Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

The PEGylated Proteins Market is primarily driven by the growing demand for effective drug delivery systems, particularly in the treatment of chronic diseases such as cancer, hepatitis, and rheumatoid ...

For example, the company is working on repressing promoter genes in tauopathies in collaboration with Biogen, but its partnership ... Fabry disease and hemophilia A (in partnership with Pfizer).

The Danish producer of diabetes drugs and insulin-delivery systems, hemophilia drugs and hormone therapies finalized ... the greater Triangle region include such major global players as Biogen, BD, ...

Investors with a lot of money to spend have taken a bearish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...

A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Biogen (BIIB – Research Report) received a Hold rating and price target from Needham analyst Ami Fadia today. The company’s shares closed last Friday at $159.99. Don't Miss our Black Friday ...

Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The results were shared at the American College of Rheumatology ...